Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2SW
|
|||
| Former ID |
DIB002340
|
|||
| Drug Name |
ASP-3291
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Astellas Pharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor (MCR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01612039) Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Drais Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.